Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus LORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus LORATADINE.
CLARITIN HIVES RELIEF REDITAB vs LORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
10 mg orally once daily
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5.
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites).
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."